3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
135
Neoplasms
37
Pancreatic Neoplasms
34
Stomach Neoplasms
27
Colonic Neoplasms
23
Neoplasm Metastasis
20
Rectal Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Esophageal Neoplasms
10
Cholangiocarcinoma
10
Adenocarcinoma
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Biliary Tract Neoplasms
8
Adenocarcinoma Of Esophagus
8
Ovarian Neoplasms
7
Triple Negative Breast Neoplasms
6
Gallbladder Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Gastrointestinal Neoplasms
5
Digestive System Neoplasms
5
Breast Neoplasms
5
Advanced Solid Tumors
5
Squamous Cell Carcinoma of Head and Neck
4
Solid Tumors
4
Melanoma
4
Intestinal Neoplasms
4
Carcinoma, Pancreatic Ductal
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumor
4
Small Cell Lung Carcinoma
3
Interventions
lutetium Lu 177 dotatate
3
Octreotide
3
pasireotide
2
lanreotide
2
amino-acid, glucose, and electrolyte solution
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
famitinib
1
copper dotatate CU-64
1
arginyllysine
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
PM 01183
1
Oxaliplatin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Leucovorin
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled